Stock Evaluator: Caribou Biosciences, Inc. (CRBU)

Caribou Biosciences, Inc. CRBU

$0.28 -0.03 -8.44%
November 20, 2026 4:00:01 PM EST November 10, 2021 Volume: 3,256,031
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Commentary & Analysis


Financial Summary

Share Statistics CRBU Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $30.7 $203.5 14%
Shares Out (Mil) 107.5 55.2 63%
Institutional Ownership 93.1% 93.3% 62%
Float (Mil) 103.7 40.4 61%
Beta 2.49 1.05 96%
Avg Daily Volume (000s) 2,428 569 84%
Price Change
(52-week)
(84.4%) 38.8% 8%
Growth CRBU Industry
Median
Percentile
(All Stocks)
Sales (5yr) (2.0%) 13.6% 13%
Net Income (5yr) (34.0%) (10.7%) 12%
EPS (5yr) 16.9% 15.4% 62
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) 57.7% (15.7%) 95%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 4 4 3
Current EPS ($0.278) ($1.035) ($0.647)
Month Ago EPS ($0.278) ($1.035) ($0.897)
# Rev Up 1 1 1
# Rev Down 1 0 0
Three Months Ago EPS ($0.363) ($1.175) ($1.263)
Year/Year Chg 12.6% (34.7%) 5.9%
Financials CRBU Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $9 $40 8%
Net Income (TTM) (Mil) ($103) ($44) 11%
EPS (TTM) ($1.027) ($1.400) 20%
Operating Cash Flow (TTM) (Mil) ($93) ($35) 6%
Net Cash Flow (TTM) (Mil) $15 $-0 61%
Long-Term Debt (Q1) (Mil) $25 $4 34%
Enterprise Value (Q1) (Mil) ($23) $142 2%
Valuation CRBU Industry
Median
Percentile
(All Stocks)
P/B 0.40 1.96 10%
P/E na 16.9 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 0.9 na
Ratios CRBU Industry
Median
Percentile
(All Stocks)
Gross Margin (797.0%) 67.6% 0%
Net Margin na (50.8%) na
ROA (64.4%) (47.0%) 9%
ROE (93.8%) (51.8%) 9%
Liabilities to Assets 37.7% 29.6% 28%
F-Score 3 3 18%

Caribou Biosciences, Inc. did not pass any screens on 11/20/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors